Articles related to DRUG SAFETY & INTERACTIONS

The FDA classified a voluntary nationwide recall involving nearly 12 million cartons of Rohto Cooling Eye Drops after a lack of assurance of sterility was identified. The action was designated a Class II recall, indicating medically reversible risks or a remote probability of serious harm.

Emerging reports suggest some patients experience emotional blunting or reduced reward responsiveness after starting GLP-1 receptor agonists. Current evidence remains mixed, and available data have not established a causal relationship between GLP-1 therapy and diminished antidepressant response.

Adults with type 2 diabetes initiating GLP-1 receptor agonists experienced higher rates of nonscarring alopecia than matched users of SGLT-2 or DPP-4 inhibitors. The association persisted across multiple analyses, though absolute risk remained low.

A Swedish register-based cohort associated GLP-1 receptor agonist use with higher relative risk of anterior ischemic optic neuropathy. Absolute event rates were low, and findings attenuated after diabetes-severity controls.

University of Oklahoma researchers identified a photoreceptor lysosomal recycling pathway regulated by PIKfyve. Mouse-model disruption produced photoreceptor degeneration and RPE changes resembling macular degeneration biology.

Benzodiazepine use among U.S. adults aged 65 years and older declined before 2020 but remained largely unchanged through 2024. Long-term use persisted in roughly one-third of users, with smaller reductions among adults aged 75 years and older.